Med List - Yola



Updated 7/21/04

This is a huge list that was compiled from the work of numerous students. Designed to be a resource for care plan drug lists, there are duplicates of popular drugs or drugs that have more than one use. Use at your own risk.

Drugs are listed here alphabetically by generic name, trade name, or both. Try searching for both names before going to the trouble of making a new entry.

To find a drug on this list, press the key combination Ctrl-F (Control-F), type the name of the drug you are looking for and press enter. Each subsequent time you press enter the next entry of the drug will be shown.

Some drugs may be listed many times in the Side Effects and Nursing Implications, which can be aggravating when using Ctrl-F. To limit the search to the first column (Drug Name), highlight that column by clicking the column's top gridline or border. The column will turn black to show it is selected. Then press Ctrl-F.

Other useful key combinations are Ctrl-Home and Ctrl-End.

|Drug Name |Class |Actions |Indications |Side Effects |Nursing implications |

|Abciximab |Inhibits platelet aggregation by |Adjunct to aspirin and heparin for | |Bleeding, including intracranial, |Monitor for S&S of: bleeding; |

|(ReoPro) |preventing fibrinogen, von |the prevention of acute cardiac | |retroperitoneal, and hematemesis; |hypersensitivity. |

| |Willebrand's factor, and other |ischemic complications in patients | |thrombocytopenia |Monitor Hgb, Hct, platelet count, |

| |molecules from adhering to |undergoing percutaneous | | |PT, APTT, INR, every 2–4 h during |

| |GPIIb/IIIa receptor sites of the |transluminal coronary angioplasty | | |first 24 h. |

| |platelets. |(PTCA). | | |Bleeding precautions. |

|Accuzyme Ointment |Indicated for debridement of |Papain, the proteolytic enzyme from| |Generally well tolerated and |Avoid cleansing with hydrogen |

|Papain-Urea 1.1 x106Unit/gm |necrotic tissue and liquefaction of|papaya, is a potent digestant of | |non-irritating. A transient |peroxide solution as it may |

| |slough in acute and chronic lesions|nonviable protein matter but is | |"burning" sensation may be |inactivate the papain. |

| |such as pressure ulcers, varicose |harmless to viable tissue. In | |experienced by a small percentage |Apply directly to the wound, cover |

| |and diabetic ulcers, burns, |Accuzyme, papain is combined with | |of patients upon applying Accuzyme.|with appropriate dressing, secure |

| |postoperative wounds, pilonidal |urea, a denaturant of proteins. | |Occasionally, the profuse exudate |into place. |

| |cyst wounds, carbuncles and |Pharmacologic studies have shown | |from enzymatic digestion may |Daily or twice daily applications |

| |miscellaneous traumatic or infected|that the combination of papain and | |irritate the skin. In such cases, |are preferred. |

| |wounds. |urea result in twice as much | |more frequent dressing changes will|Irrigate the wound at each |

| | |digestive activity as papain alone.| |alleviate discomfort until exudate |redressing to remove any |

| | | | |decreases. |accumulation of liquefied necrotic |

| | | | | |material. |

| | | | | |Papain may be inactivated by the |

| | | | | |salts of heavy metals such as lead,|

| | | | | |silver and mercury. Contact with |

| | | | | |medications containing these metals|

| | | | | |should be avoided. |

|Acetaminophen |Nonnarcotic Analgesic; |May block pain impulses | |N&V, abd. pain, hepatoxicity, |Liver function test, renal |

| |Non-salicylate, Paraminophenol |peripherally that occur in response| |stimulation, drowsiness, |function, CBC, fever or pain, I&O, |

| |Derivate Use antipyretic, |to inhibition of prostaglandin | |leukopenia, anemia, |chronic poisoning, hepatotoxicity, |

| |analgesic, treat viral infections |synthesis: antipyretic action from | |thrombocytopenia, pancytopenia, |allergic reaction |

| | |inhibition of prost CNS | |rash, angioedema, anaphylaxis |Peak: 0.5–2 h. Duration: 3–4 h |

|Acetaminophen (Tylenol) |non-narcotic analgesic |produces analgesia, reduces fever | |hepatotoxic |monitor ALT, AST |

|650 mg PO q 8 h |relief for mild pain |by direct action of hypothalamus | |elevation of ALT, AST |monitor for S/S of hepatotoxicity |

|Acetazolamide (diamox ) |Carbonic anhydrase inhibitor, |Inhibits CNS carbonic anhydrase, |Antileptic |Sedation, paresthesia, |Caution with diabetes and |

| |diuretic, CNS agent, anticonvulsant|which retards abnormal discharge | |pancytopenia, hyperglycemia, muscle|obstructive pulmonary disease. give|

| |Use: treat glaucoma, reduce seizure|from CNS neurons, inhibits carbonic| |weakness |with food, does not dissolve in |

| |activity, |anhydrase activity in the proximal | | |fruit juice |

| | |convoluted tubule, preventing the | | | |

| | |formation of carbonic acid, which | | | |

| | |enhances diuresis, inhibits aqueous| | | |

| | |humor production to lower | | | |

| | |intraocular pressure of glaucoma. | | | |

|Adriamycin, Doxorubicin |antibiotic antineoplastic |interferes with DNA and RNA |Hodgkin’s, Wilms tumor, and other |arrhythmias, acute left ventricular|cardiac function test, adequate |

|hydrochloride | |synthesis |types of cancer |failure, irreversible |hydration, premed with antiemetics,|

| | | | |cardiomyopathy, leukopenia, |never give drug IM or SQ, CBC, WBC,|

| | | | |thrombocytopenia, anaphylaxis, |monitor for signs of heart failure |

| | | | |cellulitis, tissue sloughing, |and dc if noted, wear protective |

| | | | |complete alopecia, transient red |equipment when handling |

| | | | |urine, GI effects | |

|Albumin |blood derivative |expands blood volume |hypovolemic shock, hypoproteinemia,|ha, vascular overload, 60, caution w/ hyperthyroidism, |

| |headaches |)o decrease Card outp, | |bronchconstriction, headache |can cause hypoglycemia |

| | |BP&HR, renin activity | |cold hands&feet, dreams, |use sugarless gum, eye saline, |

| | | | |heartburn, drymouth, congestn |monitor liver functions, stop med |

| | | | |caution w/ Ca chan blocker |with hepatic insufficiency |

| | | | | |caution w/ Ca channel blockers |

|cefazolin sodium (Kefzol) |antibiotic/ |binds to peniciialn-binding sites | |anaphylaxis, diarrhea |infuse over 10-60 minutes |

| | |on cell walls of suseptible | | |monitor in’s and out’s. |

|400 mg, IV q8h | |bacteria. inhibits bacterial wall | | |monitor for changes in bun and |

| |urinary tract infection |synthesis. | | |serum creatinine. |

| | | | | |report onset of diarrhea. |

|Cefepime HCl |4th-gen cephalosporin antibiotic is|Effectively treats pneumonia, skin | |Hypersensitivity Rxn: (chills, |Infuse over 30 min |

|(Maxipime) |similar to third-generation with |and soft tissue infections, febrile| |fever, skin rash, urticaria, |May cause false-positive urine |

| |broad gram-negative and |neutropenia, respiratory tract, | |shock-like state) |glucose test with Clinitest |

| |gram-positive coverage. Inhibits |intra-abdominal infections, and | |GI: Antibiotic-associated colitis, |With concurrent high-dose |

| |the third and final stage of |urinary tract infections by | |diarrhea, nausea, oral moniliasis, |aminoglycoside therapy, closely |

| |bacterial cell wall synthesis, thus|reducing or eliminating signs and | |vomiting, elevated liver function |monitor for nephrotoxicity and |

| |killing the bacteria |symptoms of infection. | |tests (ALT, AST). |ototoxicity. |

| |(bactericidal). | | |CNS: Headache, fever. |Monitor for S&S of superinfection |

| | | | |Skin: Phlebitis, pain, |or pseudomembranous colitis |

| | | | |inflammation, rash, pruritus, |Monitor for S&S of hypersensitivity|

| | | | |urticaria, |Report their appearance promptly |

| | | | |Urogenital: Vaginitis. |and discontinue drug. |

|Cefotaxime sodium |Active against a wide variety of |Broad-spectrum semi-synthetic | |Fever, nocturnal perspiration, |Determine previous hypersensitivity|

|(Kefzol) |gram-negative bacteria including |third-generation cephalosporin | |inflammatory reaction at IV site, |reactions to cephalosporins and |

| |most of the Enterobacteriaceae. |antibiotic. Preferentially binds to| |phlebitis, thrombophlebitis; pain, |penicillins before therapy is |

| |Effectively treats bone and joint |one or more of the | |induration, and tenderness at IM |initiated. |

| |infections, CNS infections, |penicillin-binding proteins (PBP) | |site, superinfections. |Monitor I&O rates and patterns: |

| |gynecologic infections and |located on cell walls of | | |Report change in I&O in patients |

| |gonorrhea, lower respiratory tract |susceptible organisms. This | |GI: Nausea, vomiting, diarrhea, |with impaired renal function or |

| |infections, intra-abdominal |inhibits third and final stage of | |abdominal pain, colitis, |with chronic UTI or who are |

| |infections, skin and urinary tract |bacterial cell wall synthesis, thus| |pseudomembranous colitis, anorexia.|receiving high dosages or an |

| |infections, and is used for |killing the bacterium. | | |aminoglycoside concomitantly. |

| |surgical prophylaxis to reduce or | | | |Monitor for Superinfection |

| |eliminate infection. | | |Skin: Rash, pruritus. |Report onset of fever, diarrhea |

| | | | | |promptly. If diarrhea is mild, |

| | | | | |discontinuation of cefotaxime may |

| | | | | |be sufficient. If diarrhea is |

| | | | | |severe, suspect |

| | | | | |antibiotic-associated |

| | | | | |pseudomembranous colitis, (may |

| | | | | |occur in 4–9 d or as long as 6 wk |

| | | | | |after cephalosporin therapy is |

| | | | | |discontinued). |

|Ceftin (Cefuroxime axetil, Zinnat) |cephalosporin antibiotic |inhibits synthesis of bacterial |dermatologic infections, UTI, |HA, dizziness, lethary, NV, |monitor vs, lab values, cultures, |

| | |cell wall causing cell wall death |septicemia, meningitis, bone and |diarrhea, bone marrow depression, |monitor for signs of anaphylaxis, |

| | | |joint infections |anaphylaxis, pn at site, increased |injection site, **no alcohol for |

| | | | |PTT &INR, anemia |three days |

|Ceftriaxone sodium |Infections caused by susceptible |Broad spectrum antibiotic. | |Fever, chills, itching (pruritus), |Determine history of |

|(Rocephin) |organisms in lower respiratory |Inhibits bacterial reproduction | |pain, inflammation of vein followed|hypersensitivity reactions to |

| |tract, skin and skin structures, |thus killing bacteria. | |by clot due to prolonged |cephalosporins and penicillins. |

| |urinary tract, bones and joints; | | |immobilization (phlebitis at IV |Inspect injection sites. |

| |also intra-abdominal infections, | | |site). |Lab tests: Perform culture and |

| |pelvic inflammatory disease, | | | |sensitivity tests before initiation|

| |uncomplicated gonorrhea, | | | |of therapy and periodically during |

| |meningitis, and surgical | | | |therapy. Periodic coagulation |

| |prophylaxis. | | | |studies (PT and INR) should be |

| | | | | |done. |

|Celebrex (Celecoxib) |nonsteroidal anti-inflammatory |inhibits prostaglandin synthesis, |treat acute pain, relief of signs |GI bleeding, diverticulitis, |Observe for GI bleeding, weight |

| |drug, COX-2 inhibitor |primarily by inhibiting |and symptoms of rheumatoid |palpitations, stiff neck, |gain, swelling of periphery, chest |

| | |cyclooxygenase-2 |arthritis in adults and of |peripheral edema |pain, or SOB |

| | | |osteoarthritis | | |

|Celebrex (Celecoxib) |Neurological System |inhibits prostaglandin synthesis, | |GI bleeding, diverticulitis, |Observe for GI bleeding, weight |

| |nonsteroidal anti-inflammatory |primarily by inhibiting | |palpitations, stiff neck, |gain, swelling of periphery, chest |

| |drug, COX-2 inhibitor |cyclooxygenase-2 | |peripheral edema |pain, or SOB |

|Celecoxi (Celebrex )bid |Nonsteroidal anti-inflammatory |Inhibits prosglandin synthesis by | |Fatigue, anxiety, depression, |Assess for pain (arthritis ) |

|Rofecoxi (Vioxx )qd | |decreasing enzyme needed for | |tachycardia, MI, fluid retention, |Monitor blood counts, decrease |

| | |biosynthesis; analgesic, | |tinnitus, blurred vision, N&V, |platelets |

| | |anti-inflammatory , antipyretic, | |anorexia, dry mouth, GI bleeding, | |

| | |properties | |Nephrotoxicity, oiguria, UTI | |

|celecoxib (celebrex) |cns agent, analgesic, cox-2 |inhibits prostaglandin synthesis by| |upper respiratory tract infection |monitor vitals |

| |inhibitor/ |inhibiting | |headache, dyspepsia, diarrhea |monitor hct , hgb, alt, AST, bun, |

| | |cox-2 | | |and creatinine |

| | | | | |monitor for pain relief |

| | | | | | |

| |pain relief | | | | |

|Celecoxib PO QD 200 mg |Nonsteroidal anti-inflammatory |Inhibits prosglandin synthesis by | |Fatigue, anxiety, depression, |Assess for pain (arthritis ) |

| | |decreasing enzyme needed for | |tachycardia, MI, fluid retention, |Monitor blood counts, decrease |

| | |biosynthesis; analgesic, | |tinnitus, blurred vision, N&V, |platelets |

| | |anti-inflammatory , antipyretic, | |anorexia, dry mouth, GI bleed, UTI | |

| | |properties | |Nephrotoxicity, oiguria, | |

|Celexa (citalopram hydrobromide) |antidepressant |potentiates serontonergic activity |treatment of depression |dizziness insomnia tremor nausea |monitor effects |

| | |in the CNS by inhibiting neuronal |particularly effective in major |dry mouth sinusitis | |

| | |reuptake of serotonin resulting in |depressive disorders | | |

| | |antidepressant effect with little | | | |

| | |effect on norepinephrine or | | | |

| | |dopamine reuptake | | | |

|CellCept |Immunosuppressive |inhibits T and B lymphocyte | |N/V/D, decrease in white blood |No antacids |

|(mycophenolate mofetil) |Prophylaxis of organ transplants |proliferation responses, blocks | |cells and platelets, anemia |CBC, monitor for signs & symptoms |

| | |antibody formation, blocks | | |of sepsis |

| | |cytotoxic T cell generation | | | |

|Cetirizine HCl (Zyrtec) |antihistamine/ |h1 histamine-receptor antagonist | |no major side effects, |monitor for reactions with other |

| | | | | |protein-bound medications. |

|10 mg. po qd at 2300 | | | |common minor side effects: | |

| |allergy symptoms | | |drowsiness, headache, sedation |monitor for sedation |

|Chlorambucil, leukeran |Alkylating drug |Cross links strands of cellular |chronic lymphocytic leukemia, |seizures, neutropenia, bone marrow |reduce initial dose if given 4 wks |

| | |DNA, interferes with RNA |malignant lymphomas including |suppression, thrombocytopenia, |after a full course of radiation or|

| | |transcription, causing imbalance of|Hodgkin's disease |myelosuppression, hepatotoxicity, |myelosuppressive drugs, or if |

| | |growth that leads to cell death. | |pulmonary fibrosis, secondary |platelet or leukocyte counts are |

| | |Not specific to cell type | |malignancies, srthyema multiforme |low, CBC with Diff, monitor for |

| | | | | |neutropenia which may not occur |

| | | | | |until after 3rd wk, monitor uric |

| | | | | |acid, anticipate blood transfusions|

| | | | | |and RBC replacement, infection |

| | | | | |control for decreased WBC pts, |

| | | | | |avoid IM injections, sz precautions|

|Chlorambucil, leukeran |Alkylating drug |Cross links strands of cellular |Atineoplastic |seizures, neutropenia, bone marrow |reduce initial dose if given 4 wks |

| |Use: chronic lymphocytic leukemia, |DNA, interferes with RNA | |suppression, thrombocytopenia, |after a full course of radiation or|

| |malignant lymphomas including |transcription, causing imbalance of| |myelosuppression, hepatotoxicity, |myelosuppressive drugs, or if |

| |Hodgkin's disease |growth that leads to cell death. | |pulmonary fibrosis, secondary |platelet or leukocyte counts are |

| | |Not specific to cell type | |malignancies, srthyema multiforme |low, CBC with Diff, monitor for |

| | | | | |neutropenia which may not occur |

| | | | | |until after 3rd wk, monitor uric |

| | | | | |acid, anticipate blood transfusions|

| | | | | |and RBC replacement, infection |

| | | | | |control for decreased WBC pts, |

| | | | | |avoid IM injections, sz precautions|

|Chlorambucil, Leukeran |Alkylating drug |Cross links strands of cellular |chronic lymphocytic leukemia, |seizures, neutropenia, bone marrow |reduce initial dose if given 4 wks |

| | |DNA, interferes with RNA |malignant lymphomas including |suppression, thrombocytopenia, |after a full course of radiation or|

| | |transcription, causing imbalance of|Hodgkin's disease |myelosuppression, hepatotoxicity, |myelosuppressive drugs, or if |

| | |growth that leads to cell death. | |pulmonary fibrosis, secondary |platelet or leukocyte counts are |

| | |Not specific to cell type | |malignancies, erthyema multiforme |low, CBC with Diff, monitor for |

| | | | | |neutropenia which may not occur |

| | | | | |until after 3rd wk, monitor uric |

| | | | | |acid, anticipate blood transfusions|

| | | | | |and RBC replacement, infection |

| | | | | |control for decreased WBC pts, |

| | | | | |avoid IM injections, sz precautions|

|Chlorhexidine Gluconate |Chlorhexidine gluconate is a |Studies have shown Chlorhexidine | |No life-threatening side effects |Explain that chlorhexidine |

|(Peridex 0.12%--blue liquid |germicidal mouthwash. It reduces |gluconate to be effective in | |are expected. (SOB; closing of the |gluconate is not to be swallowed. |

|Periogard 0.12%----blue liquid) |bacteria in the mouth. . |reducing the incidence of bacterial| |throat; swelling of the lips, face,|Swish it around the mouth and spit |

| | |pneumonia | |or tongue; or hives). |it out. |

|20 mL, Swish and Spit, Q12H | |Chlorhexidine gluconate is commonly| | |Use chlorhexidine gluconate after |

| | |used to treat gingivitis (swelling,| | |brushing |

| | |redness, and bleeding of the gums).| | |Do not dilute the solution with |

| | | | | |water or any other liquid. |

| | | | | |Avoid eating, drinking, and rinsing|

| | | | | |for at least 1 hour after using |

| | | | | |chlorhexidine gluconate. |

|Cicplatin (platinol) |Antineoplastic, alkylating agent |Produces DNA cross linking of |Atineoplastic |Ottotoxic, neuro and nephrotoxic, |Hydrate with 1-2 L fluids before |

| |Use: treat cancer |rapidly dividing cells, preventing | |peripheral neuropathy, seizures, |dose, wear gloves, EKG pre and |

| | |DNA, RNA, and protein synthesis | |ha, blurred vision, marked N&V, |during test, renal function test |

| | | | |myelosuppression, hypo Mg+, hypo |before each course of meds. |

| | | | |Ca++, SIADH | |

|Ciprofloxacin |Urinary anti-infective; |Interferes with conversion of | |Headache, dizziness, fatigue, |Sensitivity to Penicillin and |

|(Cipro) |fluoroquinolone antibacterial |intermediate DNA fragments into | |insomnia, depression, restlessness,|cephalosporins, Monitor WBC. |

| | |high molecular weight DNA in | |nausea, constipation, increased |Nephrotoxic: monitor I/O. BUN, |

| | |bacteria; DNA gyrase inhibitor | |AST, ALT, flatulence, heartburn, |Cre., urinalysis, AST, ALT, |

| | | | |vomiting, diarrhea, Candiasis, |electrolytes, bowel pattern, |

| | | | |dysphagia, rash, urticaria, |bleeding, overgrowth of infection |

| | | | |photosensitivity, flushing, fever, | |

| | | | |chills, tremor, arthralgia, tendon | |

| | | | |rupture | |

|Ciprofloxacin |Treatment of UTI Infection |Broad spectrum bacteriocidal | |Dizziness, drowsiness, insomnia, |Patients should maintain fluid |

|(Cipro) | |antibiotic. | |headache, abdominal pain, diarrhea,|intake of 1.5-2.0 L/day to prevent |

| | | | |nausea. Seizures, arrhythmias, |crystalluria. |

| | | | |pseudomembranous colitis infection.|Do not take antacids within 6 hours|

| | | | |Anaphylaxis, Steven Johnson |before taking Cipro. |

| | | | |syndrome |Assess for signs of superinfection,|

| | | | | |rash. |

|Ciprofloxacin / D5W |anti-infective, quinolone |broad spectrum bactericidal angent | |superinfections, N/V/D |Urinalysis, monitor I&O – keep well|

|premix fluid |antibiotic |that inhibits DNA-gyrase (DNA | |local burning and discomfort |hydrated |

| | |repliction in bacteria) | | | |

| | | | | | |

| | | | | | |

| | | | | | |

| | | | | | |

|Citalopram (Celexa) |SSRI |Inhibits reuptake of synaptic | |Sweating, CNS effects, joint and |Dose increments over 1 week, 2-4 |

| |Use-treat depression |serotonin | |muscle pain, hypotension, sexual |week onset, not with maoi’s, |

| | | | |dysfunction, gynecomastia |monitor fluid/electrolytes, CBC, |

| | | | | |hepatic, |

|Citalopram Hydrobromide |antidepressant |potentiates serontonergic activity |treatment of depression |dizziness insomnia tremor nausea |monitor effects |

|(Celexa) | |in the CNS by inhibiting neuronal |particularly effective in major |dry mouth sinusitis | |

| | |reuptake of serotonin resulting in |depressive disorders | | |

| | |antidepressant effect with little | | | |

| | |effect on nor epinephrine or | | | |

| | |dopamine reuptake | | | |

|Clindamycin (HCL, Palmitate, |Anti – infective; Lincomycin |Binds to 50S subunit of bacterial | |Rash, urticaria, pruritus, |Assess renal system (drug excreted |

|phosphate) |derivative |ribosomes; suppresses protein | |erythema, pain, abscess, at |via kidnerys )BC, C&S, allergic |

| | |synthesis | |injection site, N&Vabd pain , |reactions, urine output, AST, ALT, |

| | | | |diarrhea, increased AST, ALT |BUN, creatinine, Hct, bilirubin, |

| | | | |jaundice, vaginitis, urinary |electrolytes, bowel pattern, |

| | | | |frequency, leukopenia, |bleeding, overgrowth of infection |

| | | | |eosinophilia, agranulocytosis, | |

| | | | |thrombocytopenia, polyarthritis, | |

|Clonazepam (klonopin ) |CNS agent Benzodiazepine derivative|Inhibits spike, wave formation in |Sedative-hypnotic |Drowsiness, behavioral changes, |Monitor Mental status, mood, affect|

| | |absence seizures. | |Palpitation, salivation, Nausea, |blood dyscrasias, fever, sore |

| |Use: anticonvulsant | | |constipation, pancytopenia , |throat, bruising, jaundice, |

| | | | |respiratory depression, urinary |epistaxis, blood level, seizure, |

| | | | |retention |renal studies, hepatic studies, |

| | | | | |physical withdrawal, eye problems, |

| | | | | |toxicity |

|Clonidine |Anti-hypertensive |Stimulates alpha adrenergic | |dry mouth, withdrawal phenomenon, |Monitor I&O ratios, weight, Assess |

|(Catapres) |Central A-agonist, (adrenergic) |receptors in CV centers of the | |hypotension, constipation, |for edema. |

| |Use:inhibits vasoconstriction and |brainstem inhibiting | |drowsiness, sedation, |Monitor BP and pulse. |

|0.1 mg PO q4h |cardiac acceleration |cardioaccelleration and | | | |

|PRN for SBP >160 | |vasoconstriction centers | | | |

|Clopidogrel Bisulfate (Plavix) |antiplatelet agent |inhibit platelet receptor | |prolonged bleeding time |monitor for bleeding, stool blood |

|75mg Tab, PO, QD |use: inhibit clot growth |binding | |headache, hypertension |avoid NSAID stomach irritant |

| | | | |edema, inc cholesterol, fever | |

|Clozapine (Clozeril) |Atypical antipsychotic, CNS agent |Dopamine and serotonin receptor |Atypical Antipsychotic |Sedation, tachycardia |CBC, EKG, Change dosage slowly |

| |Use-treat psychotic symptoms, |block in limbic region of brain | |anticholinergic, agranulocytosis, |Change positions slowly |

| |schizophrenia | | |seizures, fever, EKG changes |Monitor for increased risk |

| | | | | |seizures, avoid ETOH |

|codeine phosphate- acetominophen |opiate agonist, analgesic/ |binds at natural opiod receptors | |minor side effects; dizziness, |monitor for pain relief, |

|2 orders: | | | |pruritis constipation, drowsiness |supervise ambulation |

|10 ml po q6h elixir prn | | | | |monitor for nausea |

| | | | | | |

|12.5 gt q4 prn |pain | | | | |

|Colchicines (novocolchine) |Anti-gout agent |Reduces migration of leukocytes to |Anti-Gout |Confusion, muscle weakness, N&V, |Caution low therapeutic index, |

| |Use: prophylaxis or treatment of |synovial fluid to inhibit | |diarrhea, agranulocytosis, bone |monitor CBC, Hgb, electrolytes, Cr,|

| |acute gout |inflammation and reduce pain and | |marrow suppression |I/O, urinalysis, Multiple peaks, |

| | |swelling of gouty arthritis | | |give with milk or food, encourage |

| | | | | |fluids IV with NS, extravasation is|

| | | | | |painful, stop drug when pain is |

| | | | | |relieved |

|copaxane (Galtiramer acetate) |  |unknown, thought to modify |MS |dreams, anxiety, agitation, |**only SQ, after administration be |

| | |processes responsible for | |diarrhea, vomiting, stomatitis, |mindful of CP, palpitations, |

| | |pathogenesis of MS | |urinary urgency, yeast infections, |anxiety, dyspnea--these signs are |

| | | | |wt gain, increased rr, dyspnea, |usually self limiting and reversed |

| | | | |vaginal hemorrhage |shortly after adm. Monitor VS, |

| | | | | |re-assess LS |

|Cozaar losartan |antihypertensive |block the binding of angiotensin 2 |treatment of hypertension |headache dizziness syncope |take without regard to meals, |

| | |to specific tissue receptors fornd | |hypotension diarrhea abdominal pain|monitor BP monitor for hypotension |

| | |in the vascula smooth muscle which | |nausea cough | |

| | |blocks the vasoconstritive effect | | | |

| | |thus leading to decrease in Bp | | | |

|Critic acid topical paste |Skin protector/ | | |N/A | |

| | | | | | |

|1 application with daiper change |diaper rash | | | | |

|Cyclosporine (sandimmune, neoral) |Immunosuppressant |Selective and reversible inhibition|Atineoplastic |Gingival hyperplasia, increase body|avoid Tacolimus, intensive dental |

| |Use: suppress the immune system to |of helper T-lymphocyts, which | |and facial hair, neuro, nephro, |care, monitor blood sugar closely, |

| |prevent transplant rejection |normally stimulate antibody | |hepatotoxic, causes hyperglycemia |monitor bun, cr, AST, alt, ldh, |

| | |production | | |neuro |

|Cytoxan, Cyclobastin, Cytoxan, |Antineoplastics |cross links strands of cellular |Atineoplastic |cardiotoxicity with very high doses|use caution with pts previously |

|Lyophilized, Procytox |Use: treat Hodgkins and multiple |DNA, and interferes with RNA |Hodgkins and multiple myeloma, and |of doxorubicin, leukopenia, |treated for cancer, don't give at |

| |myeloma, and other cancers |transcription causing an imbalance |other cancers |thrombocytopenia, hepatoxicity, |bedtime due to infrequent urination|

| | |and cell death. Not specific to | |pulmonary fibrosis with high doses,|and may lead to cystitis, dc if |

| | |cell cycle | |secondary malignant disease, |cystitis develops, monitor urine |

| | | | |anaphylaxis, GI effect |for blood, CBC, renal and liver |

| | | | | |function, monitor closely for |

| | | | | |leukopenia, monitor uric acid, may |

| | | | | |have false positive for TB, and pap|

| | | | | |smear, avoid IM if WBC 60, with |

|Lanoxin |CO, decr O2 demand of cardiac |in cell longer, thus inotropic + | |green ) bradycardia, dysrhythmias|no dysrhythmias or hold dose, |

| |tissue. Treat CHF, treat |increases cardiac contractility | | |initial loading dose of 1 mg/24hr |

| |dysrhythmias eliminated by kidney |dromotropic - chronotropic | | |0.5-2.0 ng/ml therapeutic serum |

| |use with liver disease | | | |0.125-.025mg/day normal dose- |

| | | | | |restrict Na+, monitor weight |

| | | | | |monitor K+, Na+, check trough |

| | | | | |antidote=digoxin immune fab |

|Digoxin (lanoxin) |cardiac glycoside (reduces preload |effective in treating CHF, slows | |MI, hypokalemia, digitalis |check ECG prior to admin., know K+ |

| |)has long half life (48-72hr |HR, increases cardiac | |toxicity, therapeutic level |level prior to admin., know Dig. |

| | |contractility, slows conduction | |.8-2ug/ml |Level prior to admin., apical pulse|

| | |through AV node, enhances | | |60-100, assess for Dig. Toxicity: |

| | |parasympathetic effect, mild | | |anorexia, confusion, dysrhythmias, |

| | |diuretic | | |fatigue and muscle weakness, admin.|

| | | | | |At the same time every day |

|digoxin (Lanoxin) |Cardiovascular agent, cardiac |Increases cardiac output, slows | |AV block, nausea |Take apical pulse for full minute, |

| |glycoside, antiarrhythmic |heart rate, decreases conduction | | |must be >60bpm, note rhythm and |

|Therapeutic (0.8-1.5 ng/ml) | |velocity from SA to AV | | |quality of pulse, monitor for |

| | | | | |anorexia, N&V, visual disturbances,|

| | | | | |monitor I&O, chest for rales, and |

| | | | | |edema |

|Digoxin (Lanoxin) |cardiac glycoside(reduces preload) |effective in treating CHF, slows |  |MI, hypokalemia, digitalis |check ECG prior to admin., know K+ |

| |has long half life(48-72hr |HR, increases cardiac | |toxicity, therapeutic level |level prior to admin., know Dig. |

| | |contractility, slows conduction | |.8-2ug/ml |Level prior to admin., apical pulse|

| | |through AV node, enhances | | |60-100,assess for Dig. Toxicity: |

| | |parasympathetic effect, mild | | |anorexia, confusion, dysrhythmias, |

| | |diuretic | | |fatigue and muscle weakness, admin.|

| | | | | |At the same time every day |

|Digoxin (Lanoxin) |Anti-arrhythmic. Increases |Increases force and velocity of | |hypotension, anorexia, weakness, AV|Cautious use in renal |

|0.125 mg PO q d |contractility of pt’s heart. |myocardial systolic contraction. | |block, drowsiness, dizziness |insufficiency. |

| | |Decreases conduction velocity | | |Take apical pulse before admin, |

| | |through the AV node. Increases | | |should be above 60. |

| | |contractility of heart muscle. | | |Monitor I/O, esp. in patients with |

| | | | | |renal insufficiency. |

| | | | | |Monitor serum dig levels closely. |

| | | | | |Monitor for s/s toxicity. |

|Dilantin |Anti convulsant |Inhibits spread of seizure activity|Antileptic |V Fib, insomnia, drowsiness, |Toxic levels, mental status, |

| | |in motor cortex by altering ion | |blurred vision, hepatitis, |seizure, BUN, RBC, Hct, Hgb, ALT, |

| | |transport | |nephritis, SJS, hypokalemia, N&V, |AST, eye problems, allergic |

| | | | |anorexia, HA, confusion |reaction, hepatic studies, assess |

| | | | | |physical withdrawal symptoms |

|Dilaudid (hydromorphone) |narcotic/opioid analgesics |unknown, binds with opiate |pain |bradycardia, respiratory |monitor respiratory function, |

| | |receptors in the CNS, altering both| |depression, bronchospasms, blurred |safety issues, monitor VS, have |

| | |perception of and emotional | |vision, diplopia, sedation, |Narcan available in case of |

| | |response to pain. Also suppresses | |somnolence, dizziness, euphoria, |overdose, give before pain is |

| | |the cough reflex by direct action | |**physical dependence |intense, |

| | |on the cough center in the medulla | | | |

|Diphenhydramine |Antihistamine, H1 antagonist |Binds H1 receptor and blocks |Respiratory |Anticholinergic effects, dizzy, HA,|Give with food, monitor HR, BP, |

|(Benadryl ) |Use: control bronchial secretions, |histamine release | |tingling, tachycardia, |safety, avoid ETOH, increase fluid |

|25mg PG qhs PRN |cough | | |hypo-hypertension, tinnitus, |intake |

| | | | |blurred vision, GI upset | |

|Diphenhydramine (benadryl) |Temporary symptomatic relief of |Antihistamine with significant | |Drowsiness, dizziness, headache, |Monitor cardiovascular status |

| |various allergic conditions |anticholinergic activity. | |fatigue, disturbed coordination, |especially with pre-existing |

| | | | |tingling, heaviness and weakness of|cardiovascular disease. Monitor for|

| | | | |hands, tremors, euphoria, |adverse effects especially in |

| | | | |nervousness, restlessness, |children and the older adult. |

| | | | |insomnia, confusion, (especially in|Supervise ambulation and use |

| | | | |children), excitement, fever, |side-rails as necessary. Drowsiness|

| | | | |tachycardia, dry mouth, nausea, |is most prominent during the first |

| | | | |epigastric distress, anorexia, |few days of therapy and often |

| | | | |vomiting, constipation, or |disappears with continued therapy. |

| | | | |diarrhea. | |

|Diphenhydramine HCL |antihistamine |competes with histamine for H1 | |drowsiness, confusion, insomnia, |extreme caution in pts with asthma,|

|(Benadryl) | |receptor sites on effector cells, | |HA, vertigo, sz, thrombocytopenia, |COPD, hyperplasia, intraocular |

| | |prevents but does not reverse | |anaphylactic shock, GI effects, |pressure, hyperthyroidism, CV |

| | |histamine mediated responses, | |blurred vision, fatigue, |disease, and >BP, dc 4 days prior |

| | |provides local anesthesia by | |incoordination, tremors, |to skin testing, alternate |

| | |preventing initiation and | |restlessness, agranulocytosis |injection sites, teach pts to avoid|

| | |transmission of nerve impulses, | | |alcohol |

| | |suppresses cough reflex by direct | | | |

| | |effect in the medulla | | | |

|Diphenoxylate hydrochloride with |GI agent, antidiarrheal |Synthetic narcotic similar to |GI |Ha, sedation, blurred vision, |Can crush and give with fluid of |

|atropine sulfate (lomotil) |Use: treat diarrhea |meperidine, dispensed with atropine| |paralytic ileus |choice, report abominal distension,|

| | |to discourage abuse, inhibits | | |or decreased peristalsis, monitor |

| | |mucosal receptors responsible for | | |for dehydration |

| | |peristaltic reflex | | | |

|Dipyridamole (Persantine) |antiplatelet agent |inhibit platelet receptor | |Headache, dizzy, peripheral |Give on empty stomach, protect IV |

| |non-nitrate vasodilator |binding, mild inotropic action, | |dilation, hypotension, N&V, |from direct light |

| |use: inhibit clot growth associated|little to no effect on BP and | |flushing | |

| |with prosthetic heart valves, |peripheral arteries | | | |

| |selective vasodilation of coronary | | | | |

| |arteries | | | | |

|Dipyridamole (Persantine, |anticoagulant, platelet adhesion |Inhibition of red blood cell uptake|as an adjunct to Coumadin |GI intolerance, weakness, angina or|Document mental status, skin color |

|Novo-Dipiradol) |inhibitor |of adenosine, an inhibitor of |anticoagulants in preventing |aggravation of angina, peripheral |and cardiopulmonary findings, |

| | |platelet reactivity, inhibition of |post-op thromboembolic |vasodilation |Monitor VS, ECG, CBC, PT, PTT, and |

| | |platelet phosphodiesterase which |complications, reduce risk of | |INR |

| | |leads to accumulation of cAMP |stroke in clients who have had a | | |

| | |within platelets, mild vasodilation|stroke or TIA | | |

|Divalprolex sodium |Manic episodes associated with |Decreased Manic Behavior | |Indigestion, N/V, hepatotoxicity |Assess mood, ideation, and behavior|

|(Depakote) |bipolar disorder | | | |frequently. |

|Docusate (colace) |Stool Softener (not a laxative) |Emulsifying and wetting properties,|to lessen strain of defecation in |Nausea, abd pain and cramps, |Take with full glass of water, |

|100 mg PO BID |Use: soften stool |detergent action lowers surface |persons with hernia or CV diseases,|diarrhea, bitter taste, F/E |Monitor electrolytes, I&O, assess |

| | |tension, permitting fats and water |constipation associated with dry, |imbalance |for abd pain and cramps |

| | |to penetrate stool and soften it |hard stool, bedridden clients | | |

|Docusate sodium (Dulcolax) |Laxative, emollient, stool softener|acts by lowering the surface |Prevent or treat constipation (dry,|Cramping, diarrhea, nausea |Assess for constipation, bowel |

|10 mg suppository q 12 hour PRN | |tension of the feces and promoting |hard stool); | |sounds, abdominal distention, and |

| | |penetration by water and fat, thus | | |normal patter of bowel function; |

| | |increasing the softness of the | | |withhold if diarrhea develops and |

| | |fecal mass | | |notify MD |

|Dopamine, Intropin, Revimine |sympathomimetic, adrenergic |stimulates dopaminergic and alpha |to treat shock and correct |ha, ectopic beats, tachycardia, |use caution in pts with occlusive |

| | |and beta receptors of the |hemodynamic imbalances to improve |angina, palpitations, BS, |pregnant, taking MAO inhibitors, |

| | | | | |and sulfite sensitivity, give fluid|

| | | | | |prior to vasoconstrictor, |

| | | | | |frequently monitor ECG, BP, cardiac|

| | | | | |output, CVP, pulse rate, urine |

| | | | | |output, and color and temp of |

| | | | | |extremities, titrate drug to |

| | | | | |effect, acidosis decreases |

| | | | | |effectiveness of drug, strict I & |

| | | | | |O's |

|Doxozocin (cardura ) |Alpha adrenergic antagonist |Selective inhibition of alpha |Cardiac Medication |Hypotension, HA, edema, N&V, |Give at hs, monitor BP supine and |

| |Use: treat hypertension |receptors to produce vasodilation | |leukopenia |standing 2-6 hrs post |

| | |of arteries and veins | | |administration of initial dose or |

| | | | | |increases |

|Enalapril meleate (Vasotec) |Anti HTN, Ace inhibitor |Suppresses rein angiotension – |Cardiac Medication |Dysrrtymia, HA, tinnitus, N&V, |Blood studies, B/P, orthostatic |

| |Use:treat hypertension, renal |aldosterone system to reduce | |renal failure, hypotension, |hypotension, K+ and Na+, BUN, |

| |insuffieiency |afterload by dilation of peripheral| |hyperkalemia, dyspnea, cough, dry |creatinine, renal symptoms, liver |

| | |arteries | |mouth |test, edema in feet, allergic |

| | | | | |reactions |

|Enoxaparin |Prevention of thromboembolic |Anti-coagulant. Low molecular | |Anemia, thrombocytopenia, bleeding |Assess for signs of bleeding, & |

|Lovenox |phenomena, including DVT & |weight heparinoid used for | | |hemorrhage, unusual bruising, tarry|

| |pulmonary emboli after surgical |prevention of thrombus formation. | | |black stools, hematuria, (Hct or |

| |procedures. | | | |(BP, guaiac positive stools, urine,|

| | | | | |or nasal aspirate |

|Enoxaparin sodium |Prevention of thromboembolic |Low Molecular weight heparinoid | |Anemia, thrombocytopenia, bleeding |Assess for signs of bleeding, & |

|(Lovenox) |phenomena, including DVT & |anti-coagulant. As with heparin, | | |hemorrhage, unusual bruising, tarry|

| |pulmonary emboli after surgical |these molecules enhance the effects| | |black stools, hematuria, (Hct or |

| |procedures. |of antithrombin. Because of the | | |(BP, guaiac positive stools, urine,|

| | |different mechanisms by which | | |or nasal aspirate |

| | |antithrombin and heparin | | |LMWH’s have a longer half-life and |

| | |inhibit factor IIa and factor Xa, | | |a more predictable anticoagulant |

| | |low-molecular-weight heparins do | | |response than unfractionated |

| | |not enhance the inhibition of | | |heparin, which allows for |

| | |factor IIa, but do enhance | | |subcutaneous administration without|

| | |inhibition of factor Xa. Xa is | | |laboratory monitoring. |

| | |required for activation of | | | |

| | |prothrombin. | | | |

|enoxaparin sodium (lovenox) |anticoagulant, blood former, low |antithrombotic properties- prevents| |Anemia, hemorrhage, dyspnea, |monitor aptt and tt. |

| |molecular weight heparin/ |conversion of fibrin to fibrinogen | |thrombocytopenia, angioedema |monitor cbc and platelet count, |

|30mg, sq, q12h | |and prothrombin to thrombin | | | |

| | | | | |monitor for S&S of bleeding |

| | | | | | |

| |prophylatic fo DVT | | | | |

|Enoxaparin/Lovenox injection |Blood formers; coagulators; |Anti-coagulant. Low molecular |acute and extended prophylaxis of |Angioedema, hemorrhage, pain and |Assess for signs of bleeding, & |

|30 mg SQ q 12 hours |anticoagulants; low molecular |weight heparinoid used for |DVT after surgery in those at risk |inflammation at injection site; |hemorrhage, unusual bruising, tarry|

|0800 |weight heparin |prevention of thrombus formation; |for thromboembolic complications |abnormal LFT’s; rash |black stools, hematuria, (Hct or |

| | |Does not affect PT and aPTT; |including severely restricted | |(BP; guaiac positive stools, |

| | | |mobility; with warfarin for | |urine, or nasal aspirate; get |

| | | |inpatient treatment of DVT with and| |baseline coagulation studies; |

| | | |without pulmonary embolism; with | |monitor CBC, platelet count |

| | | |aspirin to prevent ischemic | | |

| | | |complications of unstable angina | | |

| | | |and non-Q-wave MI; | | |

|Epogen |Biologic modifer |Decrease anemia with increased RBC |Endocrine |Seizure, HA, coldness, bone pain, |BUN, CR, I&O, HCT, CNS symptoms, |

|1000 units SQ MWF |Increase RBC | | | |Assess during hemodialysis, HGB, |

| | | | | |WBC, |

|Epogen, epoetin, eprex |imunomodulation |acts as a growth factor and as a |anemia due to chemo, zidovudine |sz, ha, hyperuricemia, |monitor BP, monitor hematocrit, may|

| | |differentiating factor enhancing |therapy, or end stage renal disease|hyperkalemia, hyperphosphatemia, |need heparin to prevent clotting |

| | |RBC production by acting on | |arthralgia, sob, cough, pyrexia |during dialysis treatment, CBC, |

| | |erythroid tissues in bone marrow | | |uric acid levels, supplement iron |

|EPSOM SALT |GI agent, Replacement, Saline |replenishes Mg depletion | |complete heart block, respiratory |plasma level |

|(Magnesium Sulfate) |Cathartic, anticonvulsant | | |paralysis, flushing | |

| | | | | | |

| |decreased Mg from vomiting/drug | | | | |

| |s/to relieve acute constipation | | | | |

| | | | | | |

| | | | | | |

| | | | | | |

| | | | | | |

|Erythromycin |Anti infective; Macrolide |Binds to 50S ribosomal subunits of | |Dysrhythmias, hearing loss, |WBC, C&S, allergic reactions, urine|

| | |susceptible bacteria an suppresses | |tinnitus, N&V, diarrhea, |output, BUN, creatinine, AST, SLT, |

| | |protein synthesis | |hepatotoxicity, abd pain, |CBC, Hct, electrolytes, bowel |

| | | | |stomatitis, heartburn, anorexia, |pattern for diarrhea, overgrowth of|

| | | | |pruritus, vaginitus, moniliasis, |infection |

| | | | |rash, urticaria, thrombophlebitis, | |

| | | | |anaphylaxis | |

|erythromycin |macrolide antibiotic |bacteriostatic or bactericidal in |acute infections caused by |  |  |

| | |susceptible bacteria binds to cell |sensitive strains of streptococcus | | |

| | |membrane causing change in protein |pneumonia used for Uris LRIs skin | | |

| | |function leading to cell death |and soft tissue infection caused by| | |

| | | |group a Bata hemolytic streptococci| | |

|Erythromycin eye ointment |Anti infective; Macrolide |Binds to 50S ribosomal subunits of | |Dysrhythmias, hearing loss, |WBC, C&S, allergic reactions, urine|

| |Use: treat or prevent microbial |susceptible bacteria an suppresses | |tinnitus, N/V, diarrhea, |output, BUN, creatinine, |

| |infection |protein synthesis | |hepatotoxicity, abd pain, |AST,SLT,CBC,Hct, electrolytes, |

| | | | |stomatitis, heartburn, anorexia, |bowel pattern for diarrhea, |

| | | | |pruritus, vaginitus, moniliasis, |overgrowth of infection |

| | | | |rash, urticaria, thrombophlebitis, | |

| | | | |anaphylaxis | |

|Escitalpram (Lexapro) |Antidepressant, SSRI |Inhibits reuptake of serotonin to | |Sweating, CNS effects, joint and |Dose increments over 1 week, 2-4 |

| |Use; treat depression |prolong transmission of impulse | |muscle pain, hypotension, sexual |week onset, not with MAOIs, monitor|

|10mg Tab, PO,QD | |across neural synapse | |dysfunction, gynecomastia, dose is |fluid/electrolytes, CBC, hepatic |

| | | | |minimized to reduce occurrence of |monitoring |

| | | | |side effects | |

|Escitalpram Oxalate (Lexapro) |Treatment of depression |SSRI. Selectively inhibits the | |Insomnia, diarrhea, nausea |Monitor mood changes |

| | |reuptake of serotonin in the CNS. | | |Assess for suicidal tendencies, |

| | | | | |especially during early therapy. |

|Ferrous Sulfate |Supplement for iron deficiency |Absorbed in GI | |Constipation, dark tarry stools, |Give on empty stomach, better |

| |anemia |supplements systemic mineral iron | |nausea, heartburn, anorexia, |absorbed with acidic drink such as |

|40 mg PO QD | |supply | |constipation, diarrhea, epigastric |orange juice, can cause |

| | | | |pain, abdominal distress, black |constipation and dark stool . |

| | | | |stools. Yellow-brown discoloration |Monitor hemoglobin, RBC’s and |

| | | | |of eyes and teeth. |hematocrit |

|Ferrous sulfate |To correct simple iron deficiency |Reverse iron deficiency, gastric, | | |Monitor Hgb; Continue iron therapy |

|(Fer-In-Sol Drops) |and to treat iron deficiency |esophageal, and other tissue | | |for 2–3 mos after the hemoglobin |

| | |changes caused by lack of iron. | | |level has returned to normal; |

| | | | | |Monitor bowel movements as |

| | | | | |constipation is a common adverse |

| | | | | |effect. |

|Fexofenadine (allegra ) |Antihistamine H1 receptor |Antagonize histamine at the H1 |Respiratory |Has no anticholinergic or sedative |Well tolerated with minimal side |

| |antagonist |receptor, inhibits bronchospasms | |action, HA, drowsy fatigue, nausea |effects |

| |\use: treat seasonal allergies |and histamine release from mast | | | |

| | |cells | | | |

|Filgrastim |To decrease the incidence of |Human granulocyte | |Bone pain, hyperuricemia, fever |Obtain CBC twice weekly during |

|(neupogen) |infection, as manifested by febrile|colony-stimulating factor (G-CSF) | | |therapy to monitor neutrophil count|

|Human granulocyte colony-stimulating|neutropenia, to treat chronic |produced by recombinant DNA | |CV: Abnormal ST segment |and leukocytosis. |

|factor (g-csf) |neutropenia. |technology. Endogenous G-CSF | |depression, MI and arrhythmias | |

| | |regulates the production of | | |Monitor Hct and platelet count |

| |Increases neutrophil proliferation |neutrophils within the bone marrow;| |Hematologic: Anemia. |regularly. |

| |and differentiation within the bone|not species specific and primarily | | | |

| |marrow |affects neutrophil proliferation, | |GI: Nausea, anorexia. | |

| | |differentiation and selected | | |Monitor temperature q4h. Incidence |

| | |end-cell functional activity | | |of infection should be reduced |

| | |(including enhanced phagocytic | | |after administration of filgrastim.|

| | |activity, antibody-dependent | | | |

| | |killing, and the increased | | | |

| | |expression of some functions | | |Assess degree of bone pain if |

| | |associated with cell-surface | | |present. Consult physician if |

| | |antigens). | | |non-narcotic analgesics do not |

| | | | | |provide relief |

|Flomax (Tamsulin hydrochlordie) |anti-adrenergic blocker |it blocks the alpha1 adrenergic |treatment of signs and symptoms of |headache, back pain, postural |monitor for orthostatic hypotension|

| | |receptors in th prostate, |BPH |hypotension, dizziness, vertigo, |monitor to see if urine out put has|

| | |prosthetic capsule prostatic | |abnormal ejaculation, amblyopia |increased, advise client of sexual |

| | |urethra and bladder neck leading to| | |side effects and how to deal with |

| | |relaxation of bladder and prostate | | |them, note PSA levels and results |

| | |and improving urine flow | | |of digital rectal exam |

|Flomax (Tamsulin hydrochloride) |anti-adrenergic blocker |it blocks the alpha1 adrenergic |treatment of signs and symptoms of |headache, back pain, postural |monitor for orthostatic hypotension|

| | |receptors in the |BPH |hypotension, dizziness, vertigo, |monitor to see if urine out put has|

| | |prostate,prosthetic capsule | |abnormal ejaculation, amblyopia |increased, advise client of sexual |

| | |prostatic urethra and bladder neck | | |side effects and how to deal with |

| | |leading to relaxation of bladder | | |them, note PSA levels and results |

| | |and prostate and improving urine | | |of digital rectal exam |

| | |flow | | | |

|Fluconazole |Antifungal properties are related |Fungistatic; may also be fungicidal| |CNS: Headache. |Incompatible in Solution with |

|(diflucan) |to the drug effect on the fungal |depending on concentration. | | |Trimethoprim-sulfamethoxazole. |

| |cell membrane functioning. |Interferes with formation of | |GI: Nausea, vomiting, abdominal |Monitor for allergic response. |

| | |ergosterol, the principal sterol in| |pain, diarrhea, increase in AST in |Patients allergic to other azole |

| | |the fungal cell membrane that when | |patients with cryptococcal |antifungals may be allergic to |

| | |depleted interrupts membrane | |meningitis and AIDS. |fluconazole. |

| | |function. | | |Lab tests: Monitor BUN, serum |

| | | | |Skin: Rash |creatinine, and liver function. |

| | | | | |Note: Drug may cause elevations of |

| | | | | |the following laboratory serum |

| | | | | |values: ALT, AST, alkaline |

| | | | | |phosphatase, bilirubin. |

| | | | | |Monitor for S&S of hepatotoxicity |

|Fluconazole (Diflucan ) |Antiinfective, antibiotic, |Fungistatic by depleting major | |HA, N&V, AB pain, rash |Administer drug post hemodialysis, |

| |Antifungal |sterol of fungal cell membrane | | |monitor BUN, CR, liver function |

| |Use: treat oralpharyngeal and | | | | |

| |systemic candidiasis | | | | |

|Fluconazole (Diflucan) |antifungal |inhibits the enzyme cytochrome |oropharyngeal and esophageal |dyspepsia, headache, seizures, |Obtain baseline cultures, renal and|

| | |P-450 in the organism which results|candidiasis, maintenance therapy to|hepatic reactions, |LFTs, monitor closely for liver |

|40 mg PO qd | |in decrease in cell wall integrity |prevent cryptococcal meningitis in |hypercholesterolemia, hypokalemia |toxicity, monitor CBC, monitor VS, |

| | |and extrusion of intracellular |AIDS clients, vaginal candidiasis | |mental status Obtain baseline |

| | |material, leading to cell death | | |cultures |

| | |decrease yeast production | | | |

|Fluoxetine HCl (Prozac )PO 40 mg qd |Serotonin reuptake inhibitor |Inhibits reuptake of neuronal | |Headache, insomnia, rash drowsy, |Caution diabetes, give in AM |

| |Use-treat depression |serotonin | |N&V, anorexia, wt loss, menstrual |2-3 weeks onset therapeutic |

| | | | |irregularity, anticholinergic |effects, monitor Na |

| | | | |effects | |

|Fluphenazine hydrochloride (Prolixin|CNS depression, antipsychotic |Block post synaptic dopamine |Typical Antipsychotic |High EPS, low sedation and |Can be given IM for treatment |

|)chlorpromazine hydrochloride |Use-treat psychosis |receptors in the brain | |hypotensive effects, convulsions, |q2weeks for noncompliant clients. |

|(Thorazine) |CNS depression, antipsychotic |Block post synaptic dopamine | |problems with thermoregulation |change positions slowly, avoid |

| |Use-treat psychosis and manic phase|receptors in the brain | |tardive dyskinesia, High sedation, |overheating and extreme cold, avoid|

| |of bipolar disorder excessive | | |EPS and hypotensive effects, |sunlight and ETOH, monitor aims, |

| |agitation or anxiety, antiemetic | | |problems with thermoregulation, |onset 2-3 weeks |

| | | | |weak anticholinergic, direct | |

| | | | |cardiac depression | |

|Fluticasone (advair) |Adrenal corticosteroid |Opens airways by reducing chronic |Respiratory |Masked infection, , dry mouth |Hold powder in with breath. Not for|

| |anti-inflammatory |inflammation of airway | |Bad taste |acute attacks of |

| |Use:open airways by reducing | | | |bronchoconstriction. Rinse mouth |

| |inflammation | | | |after use |

|Fluticasone propionate (Flonase, |Glucocorticoid |Regulate the metabolic pathways |Used for anti-inflammatory or |edema, hypokalemic alkalosis, |Note mental status, check for |

|Cutivate, Flovent, Flovent Rotadisk)| |involving protein, carbohydrate and|immunosuppressant therapy; |hypokalemia, hypocalcemia, |allergic reactions, monitor ECG, |

| | |fat, anti-inflammatory effect |replacement therapy, rheumatic |hypotension, peptic ulcers, |electrolytes, BS, UA, renal and |

| | |because of their ability to inhibit|disorders, collagen diseases, |Cushing's syndrome, vertigo, |LFTs, document VS and weight |

| | |prostaglandin synthesis, inhibit |allergic diseases, respiratory |cardiac arrhythmias | |

| | |accumulation of macrophages and |diseases, etc. | | |

| | |leukocytes at sites of inflammation| | | |

|Folic Acid (Vitamin B9) |Vitamin B9 supplement required for |B complex component stimulates the | |Non-toxic; may have flushing and |monitor VS, loc, and lung sounds |

|(Folacin, Folvite) |nucleoprotein synthesis and |production of RBC’s, WBCs and | |warmth after IV administration. |**teach pt to eat foods high in |

| |maintenance of normal |platelets by bone marrow | |bronchospasms, confusion, |folic acid--liver, oranges, whole |

| |erythropoiesis. |Folate deficiency; macrocytic | |difficulty concentrating, anorexia,|wheat, broccoli, brussel sprouts; |

| |Use: treat folic acid deficiency, |anemia; megaloblastic anemia; | |and nausea…..may reduce RBC |Monitor for improvements in anemic |

| |macrocytic anemia associated with |alcoholism; primary liver disease; | | |states |

| |malabsorption |inadequate dietary intake; | | |Monitor client’s nutritional status|

| | |pregnancy; | | |monitor pts on phenytoin for |

| | | | | |subtherapeutic levels; |

|fosamax (alendronate sodium) |uncategorized drug |suppresses osteoclast activity on |prevention of osteoporosis in |ha, abd pain, nausea, constipation,|monitor VS, monitor gastric |

| | |newly formed resorption surfaces, |post-men. women, old compound |diarrhea, acid regurgitation, |problems esp. due to gastric hx, |

| | |which reduces bone turnover. Bone |fractures T-12, |esophageal ulcer, vomiting, |bowel regimen, monitor stools |

| | |formation exceeds resorption at | |musculoskeletal pain | |

| | |remodeling sites, leading to | | | |

| | |progressive gains in bone mass | | | |

|Furosemide |Anti-hypertensive and management of|Loop diuretic. Inhibits | |Dehydration, hyperchloremia, |Monitor BP and pulse, I&O, weight.|

|(Lasix) |edema secondary to CHF. |reabsorption of Na+ and Cl- from | |hypokalemia, hypomagnesemia, |Edema, lung sounds, skin turgor, |

| | |the Loop of Henle and Distal Renal | |hyponatremia, hypovolemia, |mucous membranes. Monitor for |

| | |Tubule increasing renal output, | |metabolic acidosis |symptoms of dehydration. |

| | |thus lowering BV and BP. | | | |

|furosemide (Lasix) |Loop diuretic, electrolytic and |Diuretic and antihypertensive, | |Hypokalemia, circulatory collapse, |Give with food or milk, give am, |

| |water balance agent |inhibits reabsorption of sodium and| |aplastic anemia, agranulocytosis |store oral in refrigerator, protect|

| | |chloride, magnesium and potassium | | |syringes from light, watch for |

| | |wasting diuretic | | |possible digoxin toxicity due to |

| | | | | |hypokalemia |

|Furosemide (Lasix) |Loop diuretic. Anti-hypertensive |Inhibits reabsorption of NaCl, | |hypokalemia, circ. collapse, |Monitor BP and pulse, I&O, weight. |

|80 mg PO q d |and management of edema |primarily in the loop of Henle. | |agranulocytosis, orthostatic |Edema, lung sounds, skin turgor, |

| | |Anti-hypertensive that decreases | |hypotension, hyponatremia, |mucous membranes. Monitor for |

| | |edema and intravascular volume. | |hypovolemia, hypomagnesemia, |symptoms of dehydration |

| | | | |hypocalcemia, elevated bun, | |

| | | | |metabolic acidosis | |

|Gabapentin (Neurontin ) |CNS agent/ anticonvulsant |GABA neurotransmitter analog, | |Drowsy, dizzy, tremor, slurred |Do not give with antacids, monitor |

| |Use-treat bipolar disorder |effect on neuronal serotonin | |speech, headache, impaired |neurologic signs |

|2-100 mg Capsule TID, PO |and depression |metabolism postulated | |concentration, wt gain, N&V, | |

| | | | |blurred vision | |

|600mg PO, Day | | | | | |

|Gabapentin (Neurontin) |Treatment of severe pain |Gabapentin is primarily used as an | |Drowsiness, ataxia, anxiety |Assess for location, intensity, and|

| | |anticonvulsants. It has an | | |characteristics of pain |

| | |unlabeled use in the treatment of | | |periodically |

| | |severe pain. | | | |

|Gatifloxacin (tequin) |Anitibiotic, quinolone |Effects the nucleic acid metabolism|acute bacterial exacerbation of |acute hepatitic necrosis or |Dilute according to package insert,|

| | |inhibiting DNA-dependent RNA |chronic bronchitis, acute |failure, fever, chills, tremors, |give by IV infusion over 60 mins, |

| | |polymerase or inhibition of gyrase |sinusitis, community-acquired |abdominal pain, hemolytic anemia, |do not add additives or other |

| | |(Cells cannot duplicate or |pneumonia, UTI, pyelonephritis, |rash, complete prescription, avoid |medications or use through same |

| | |reproduce) |gonorrhea, rectal infections |activities that require mental |line, flush line before and after |

| | | | |alertness, report hear palpitaitons|admin., |

| | | | |and fainting | |

|Gatifloxacin (tequin) |Urinary anti-infective; |Interferes with conversion of | |Headache, dizziness, insomnia, |WBC, C&S, allergic reactions, urine|

| |Fluroquinolone antibacterial |intermediate DNA fragments into | |paresthesia, tremor, vasodilation, |output, BUN, creatinine, AST, ALT |

| | |high-molecular weight DNA in | |nausea, constipation, increased |CBC, HCT, electrolytes, bowel |

| | |bacteria; DNA gyrase inhibitor | |AST, ALT, diarrhea, |pattern for diarrhea, bleeding, |

| | | | |pseudomembranous colitis, rash, |overgrowth of infection |

| | | | |urticaria, photosensitivity, | |

| | | | |flussing, fever chills, dyspnea, | |

| | | | |pharyngitiis | |

|Gel wound dressing |Wound covering | | | | |

| |Use: protect wound and promote | | | | |

| |healing | | | | |

|Gentamicin |Anti-infective; Aminoglycoside |Interferes with protein synthesis | |Confusion, tremors, convulsions, |WBC, C&S, allergic reactions, urine|

| | |in bacterial cell by binding to | |neurotoxicity, vertigo, hyper- |output, AST, ALT, CBC, Hct, |

| | |ribosomal subunit, causing | |hypotension, palpitations, |electrolytes, bleeding, overgrowth |

| | |misreading of genetic code; | |ototoxicity, tinnitus, N&V, |of infection, weight, I&O, |

| | |bacterial death | |anorexia, Hepatic necrosis, |proteinuria, VS for hyper – |

| | | | |splenomegaly, oliguria, hematuria, |hypotenstion, IV site for |

| | | | |renal damage, nephrotoxicity, rash,|throbocytopenia, serum peak 30-60 |

| | | | |alopecia, leukopenia, anemia, |after adm, PH, deafness, |

| | | | |thrombocytopenia |dehydration |

|gentamicin sulfate |aminoglycoside |bactericidal inhibits protein |serious infections caused by |tinnitus dizziness numbness nausea |monitor for the nausea and vomiting|

| | |synthesis in susceptible strains of|susceptible strains of pseudomonas |vomiting anorexia pain irritation |give small meals monitor signs to |

| | |gram negative bacteria appears to |aeruginosa for serious infection |locally |see if drug is working or not |

| | |disrupt functional integrity of |when causative agent is unknown | |culture site |

| | |bacterial ell membrane causing cell| | | |

| | |death | | | |

|Glipizide |Antidiabetic agent |Stimulates insulin release from | |Hypoglycemia Anorexia, nausea, |Monitor glucose levels |

|10 MG PO BID-A |Sulfonylurea |functioning beta cells in the | |vomiting, epigastric discomfort, |Monitor for s/s of hypoglycemia |

| | |pancreas; may improve binding | |heartburn, diarrhea Leukopenia, | |

| | |between insulin and insulin | |thrombocytopenia, anemia | |

| | |receptors or increase the number of| | | |

| | |insulin receptors; more potent in | | | |

| | |effect than first-generation | | | |

| | |sulfonylureas | | | |

|Glipizide (Glucotrol XL ) |Antidiabetic, sulfonylurea 2nd |Stimulates beta cells of pancreas | |N&V, diarrhea, constipation, HA, |Do not crush, not with ETOH, do not|

| |generation |to secrete insulin, increases | |vision disturbance |use with diabetic ketoacidosis, |

|5mg PO QD ,30 min AC |Use: treat diabetes type 2 |insulin sensitivity of receptors, | | |take 30 min p first meal of day, do|

| | |inhibits hepatic glucose production| | |not substitute, BS testing is still|

| | | | | |necessary |

|Glucophage (Metformin hydrochloride)|antidiabetic agent |exact mechanism is not understood, |adjunct to diet to lower blood |hypoglycemia, lactic acidosis, |monitor urine or serum glucose |

| | |possibly increases peripheral |glucose in patients with |anorexia nausea vomiting, |levels frequently to determine |

| | |utilization of glucose increases |non-insulin dependent diabetes |epigastric discomfort, heart burn |effectiveness of drug and dosage |

| | |production of insulin decreases |mellitus type 2 in patients greater|diarrhea allergy |monitor for hypoglycemia |

| | |hepatic glucose production and |than or equal to 10 years old | | |

| | |alters intestinal absorption of | | | |

| | |glucose | | | |

|Glucotrol (glipizide) |antidiabetic agent |stimulates insulin release form |adjunct to diet to loer blood |anorexia, nausea, vomiting, |give drug before breakfast monitor |

| | |functioning Beta cells in the |glucose in patients with |epigastric discomfort, heartburn |glucose levels to assure drug is |

| | |pancreas may improve binding |non-insulin dependent diabetes |hypoglycemia, |working monitor for signs of |

| | |between insulin recdeptors or |mellitus type 2 | |hypoglycemia |

| | |increase the number of insulin | | | |

| | |receptors | | | |

|Gold sodium thiomalate |Gold compound |immunomodulary and | |Dizzy, sweating, flushing, N&V, |Shake well, inject deep muscle with|

| |Use: treat acute rheumatoid |anti-inflammatory, inhibition of | |metal taste, hepatitis, |patient recumbent for 30 min, |

| |arthritis, felty’s syndrome |prostaglandid synthesis | |agranulocytosis, aplastic anemia, |monitor urine for protein, blood, |

| | | | |renal disease, alopecia, gray or |sediment and skin for purities |

| | | | |blue skin pigment (chrysiasis ) |before each dose, monitor WBC, RBC,|

| | | | |puritis |Hbg, platelets, avoid sunlight, |

| | | | | |slow effects |

|Guaifenesin |expectorant |increase output of the resp.tract |use for nonproductive cough |nv, gi upset, dizziness, h/a, rash |document pulmonary assess., cough, |

| | |by reducing the viscosity and | | |and sputum prod., document fever, |

| | |surface tension of resp.secretions,| | |chills. Don't perform activities |

| | |facilitating expectoration | | |that require mental alertness. |

|Guaifenesin |expectorant |increase output of the resp.tract |use for nonproductive cough |N/V, GI upset, dizziness, rash |Document pulmonary assess., cough, |

|(Robitussin syrup) | |by reducing the viscosity and | | |and sputum prod. |

| | |surface tension of resp.secretions,| | |Document fever, chills. |

|200mg PO q4h PRN | |facilitating expectoration | | |Don't perform activities that |

| | | | | |require mental alertness. |

|Guaifenesin |expectorant |increase output of the resp.tract |use for nonproductive cough |N/V, GI upset, dizziness, rash |Document pulmonary assess., cough, |

|(Robitussin syrup) | |by reducing the viscosity and | | |and sputum prod. |

| | |surface tension of resp.secretions,| | |Document fever, chills. |

|200mg PO q4h PRN | |facilitating expectoration | | |Don't perform activities that |

| | | | | |require mental alertness. |

|Guaifenesin PO Q4H, 300 mg |Expectorant |Acts as an expectorant by |Respiratory |Drowsiness, N&V, anorexia, |Assess cough, fluid increase, |

| | |stimulating a gastric mucosal | |vomiting, | |

| | |reflex to increase the production | | | |

| | |of lung mucus | | | |

|Halcion |sed/hypnotic |CNS depressant, blocks |Sedative-hypnotic |caution:preg X, hypersensitivity |rapid onset, smoking decreases |

|Triazolam |benzodiazepine |cortical & limbic arousal | |impaired hepatic, renal, resp |effects, withdrawal S&S with |

|0.125-.25mg/d |use:short term treatmnt |onset 15-30 min. | |side/adv-headache, dizzy |suddenly stopping drug, no |

|PO |of insomnia |duration 6-8 hr. causing | |ataxia, memory loss, |alcohol |

| | |hypnotic sleep with | |vision change, nausea | |

| | |few residual day effects | |paradox rage | |

|Haloperidol (Haldol) |Antipsychotic, CNS depression |Typical Antipsychotic | |High EPS effects, low sedation and |Monitor EKG, change positions |

| |Use-treat agitated states of |Dopamine antagonist | |hypotension activity |slowly, avoid overheating and |

| |psychoses, antiemetic |Ach, Histamine, alpha receptor | |problems with thermoregulation , |extreme cold, avoid sunlight and |

| | |antagonist | |ventricular dysrhythmia |ETOH, monitor aims, onset 2-3 weeks|

|Haloperidol (Haldol) |antipsychotic |decreases psychotic manifestations | |acetaminophen (Tylenol) |non-narcotic analgesic |

|2mg IV q 6 h |relieve client’s anxiety |and exerts antiemetic effect | |650 mg PO q 8 h |relief for mild pain |

|HCTZ 25MG PO QD |Thiazide diuretic- helps reduce |Inhibits reabsorption of sodium and| |Dizziness, vertigo, paresthesias, |Monitor client’s urinary output |

| |blood pressure b removing excess |chloride in distal renal tubule, | |weakness, headache, drowsiness, |Monitor client’s weight regularly |

| |water |increasing the excretion of sodium,| |fatigue, leukopenia, |Teach client to avoid sudden |

| | |chloride, and water by the kidney. | |thrombocytopenia, agranulocytosis, |changes in position |

| | | | |aplastic anemia, neutropenia |Monitor for s/s of dehydration |

| | | | |Orthostatic hypotension, venous |Monitor client’s sodium and |

| | | | |thrombosis, volume depletion, |potassium levels |

| | | | |cardiac arrhythmias, chest pain | |

| | | | |Nausea, anorexia, vomiting, dry | |

| | | | |mouth, diarrhea, constipation, | |

| | | | |jaundice, hepatitis, pancreatitis | |

| | | | |Polyuria, nocturia, impotence, loss| |

| | | | |of libido | |

|Heparin |anticoagulant |Inhibits thrombus and clot |prevention and treatment of venus |uncontrolled bleeding;bruising; |monitor PTT, monitor K+ levels, |

| | |formation by blocking the |thrombosis; pulmonary embolism; and|hyperkalemia; suppression of renal |teach pt. about avoiding sharp |

| | |conversion of prothrombin to |a-fib with embolization |functions (long-term high dose |objects, watch for bleeding when |

| | |thrombin and fibrinogen to fibrin | |therapy) |brushing teeth, apply pressure to |

| | |the final steps in the clotting | | |all injection sites, do not give IM|

| | |process | | |injections to pt. on heparin |

|Heparin |Anticoagulant as prophylaxis for |Inhibits thrombus and clot | |Bruising; thrombocytopenia; |Monitor client’s PTT levels |

|5000U= 0.5mL (10,000 unit mL) |DVT |formation by blocking the | |elevated AST, ALT levels, |Monitor client for occult stool |

|SC Q12H | |conversion of prothrombin to | |hyperkalemia Chills, fever, |Monitor client for bruising and |

| | |thrombin and fibrinogen to fibrin, | |urticaria, asthma |evidence of bleeding |

| | |the final steps in the clotting | | | |

| | |process. | | | |

|heparin sodium | |Accelerates formation of | |Anaphylaxis, Hemorrhage, |Draw baseline PTT |

|5,000 Units SQ Q12º |Intrinsic Anticoagulant |antithrombin-III-thrombin complex | |Thrombo-cytopenia, White clot |Do not aspirate before or massage |

| | |and deactivates thrombin preventing| |syndrome |after injection |

| |DVT Prophylaxis |conversion of fibrinogen to fibrin.| | |Monitor PTT and platelet count |

| | | | | |regularly |

| | | | | |Monitor for bruises, petechiae, |

| | | | | |hematuria, hematemesis, or melena |

|Heparin sodium |Prophylaxis (prevents disease) and |Strongly acidic, high molecular | |Spontaneous bleeding, fever, |Lab tests: Baseline blood |

|IV  50 u/kg bolus, then 20,000 |treatment of venous thrombosis and |weight mucopolysaccharide with | |chills, skin rashes, itching and |coagulation tests, Hct, Hgb, RBC, |

|u/m2/24 h or 50–100 u/kg q4h or |pulmonary embolism |rapid anticoagulant effect. | |burning sensations of feet, |and platelet counts prior to |

|15–25 u/kg/h=range 4,284u-7,140u | | | |numbness and tingling of hands and |initiation of therapy and at |

| | | | |feet, elevated BP, headache, nasal |regular intervals throughout |

|Dose: 10,000 units iv flsk | | | |congestion, suppressed renal |therapy. Monitor vital signs. |

|10 units iv qd | | | |function, injection site reactions:|Report fever, drop in BP, rapid |

|10 units iv flsk | | | |pain and itching |pulse, and other S&S of hemorrhage.|

| | | | | |Observe all needle sites daily for |

| | | | | |inflammation. |

|Heparin Sodium |Intrinsic Anticoagulant |Accelerates formation of | |Anaphylaxis, Hemorrhage, |Draw baseline PTT |

|5000 Units/ SQ/ Q8H | |antithrombin-III-thrombin complex | |Thrombo-cytopenia, White clot |Do not aspirate before or massage |

| |DVT Prophylaxis |and deactivates thrombin preventing| |syndrome |after injection |

| | |conversion of fibrinogen to fibrin.| | |Monitor PTT and platelet count |

| | | | | |regularly |

| | | | | |Monitor for bruises, petechiae, |

| | | | | |hematuria, hematemesis, or melena |

|Heparin sodium (pork) |Anti-coagulant, used to flush IV |Strongly acidic, high molecular | |Spontaneous bleeding, Injection |Lab tests: Baseline blood |

| |access to prevent thrombosis. |weight mucopolysaccharide with | |site reactions: pain, itching, |coagulation tests, Hct, Hgb, RBC, |

| | |rapid anticoagulant effect. | |ecchymoses, tissue irritation and |and platelet counts prior to |

| | |Prepared from bovine lung tissue or| | |initiation of therapy and at |

| | |porcine intestinal mucosa. | | |regular intervals throughout |

| | | | | |therapy. |

|Heparin Sodium Drip |Cardiovascular System |Accelerates formation of | |Anaphylaxis, Hemorrhage, |Draw baseline PTT |

|25000 Unit in D5W 250mL |Intrinsic Anticoagulant |antithrombin-III-thrombin complex | |Thrombo-cytopenia, White clot |Do not aspirate before or massage |

|(100units/mL premix) | |and deactivates thrombin preventing| |syndrome |after injection |

|IV / PRN |DVT Prophylaxis |conversion of fibrinogen to fibrin.| | |Monitor PTT and platelet count |

| | | | | |regularly |

| | | | | |Monitor for bruises, petechiae, |

| | | | | |hematuria, hematemesis, or melena |

|Heparin sodium, pork |Anticoagulant |Block clotting cascade to prevent | |Bleeding,bruising |Monitor for bruising and bleeding, |

| |Use:treat or prevent DVT, CVA |clot from increasing | | |rotate site |

|Hespan, hetastarch |electrolyte |expands plasma volume and provides |plasma expander, continuous flow |ha, edema of legs and eyes, n/v, |use caution in pts with liver |

| | |fluid replacement |centrifugation leukapheresis |dilution of clotting factors, fluid|dysfunction, not a substitute for |

| | | | |overload, muscle pain, wheezing, |blood or plasma, monitor renal |

| | | | |fever, urticaria |function, dc if allergic reaction, |

| | | | | |when giving for continuous flow |

| | | | | |centrifugation, usually use one |

| | | | | |part hetastarch to eight pars |

| | | | | |venous whole blood |

|Hydralazine (apresoline) |antihypertensive, vasodilator |unknown, a direct-acting |used for hypertension |orthostatic hypotension, |explain to client about orthostatic|

| | |vasodilator that primarily relaxes | |tachycardia, edema, angina |hypotension monitor BP to see if or|

| | |arteriolar smooth muscle | | |how it is working. Monitor CBC for |

| | | | | |decrease in neutrophil, WBC, |

| | | | | |platelet and RBC's |

|Hydrochlorothiazide (Esidrex, Ezide,|Diuretic, thiazide |Promote diuresis by decreasing the |Edema, CHF, hypertension, |electrolyte imbalances, |Monitor CBC, glucose, electrolytes,|

|hydrodiuril, Oretic | |rate at which sodium and chloride |premenstrual tension, nephritis, |parethesias, orthostatic |Ca, Mg, renal and LFTs, Check uric |

| | |are reabsorbed by the distal renal |renal failure, hepatic cirrhosis |hypotension, MI, photosensitivity, |acid levels, Assess skin turgor, |

| | |tubules of the kidney, force | |hyperglycemia, blurred vision |mucous membranes, extremities, lung|

| | |excretion of additional water, | | |sounds, avoid K+ depletion in |

| | |increase excretion of potassium, | | |cirrhosis and hepatic |

| | |and bicarbonate, as well as | | |encephalopathy |

| | |decrease the excretion of calcium | | | |

| | |and uric acid | | | |

|Hydrochlorothiazide (Hydrodiuril ) |Thiazide diuretic |Diuretic. Enhances transport of Na+| |Hypokalemia, hypercalcemia, |Change positions slowly, monitor |

| |Use: treat edema of CHF, |ions across renal tubule, causing | |hypotension mood changes, weakness,|electrolytes, (especially K+ ) |

|25mg, PO, QD, P |hypertension |excretion of Na+, CL, K+, HCO3 and | |paresthesia, dry mouth, |bun, |

| |renal disease |water | |agranulocytosis |creatinine, monitor BP, I/O, may |

| | | | | |cause hyperglycemia and lose of |

| | | | | |glucose control |

|Hydrocodone 5mg/ Acetaminophen 500 |Opioid with acetaminophen, |Action similar to codeine, but more| |Side effects less than morphine: |Monitor respirations |

|mg |Use: analgesic for moderate to |addicting, CNS opioid receptor | |Constipation, N&V, drowsy, resp |Monitor for pain relief |

|(Vicodin / Lortab) |moderately severe pain and anxiety |binding | |depressionn, |monitor vitals |

| |inhibit cough | | |Orthostatic hypotension, urinary |give with food or milk |

|2 tab / PRN / | |Suppresses cough reflex | |retention |monitor bowel elimination |

|Max APAP=4000 mg/day | | | | | |

|Hydrocodone 5mg/ Acetaminophen 500 |Opioid with acetaminophen, |Action similar to codeine, but more| |Side effects less than morphine: |Monitor respirations |

|mg |Use: analgesic for moderate to |addicting, CNS opioid receptor | |Constipation, N&V, drowsy, resp |Monitor for pain relief |

|(Vicodin) |moderately severe pain and anxiety |binding | |depression, |monitor vitals |

|2 tabs PO q 6 hours PRN |inhibit cough |Relief of moderate to moderately | |Orthostatic hypotension, urinary |give with food or milk |

| | |severe pain; suppress cough | |retention | |

|Hydrocolloid dressing |Flexible hydroactive dressing |Flexible hydroactive dressing that |Skin |Microbial infection masked |Clean wound before application. |

|(Duoderm ) |Use: local management of pressure |controls the asorption of wound | | |Leave in place 1-7 days. |

| |ulcers, sores with diabetes |fluid exudates by interaction with | | |Discontinue and treat with |

|wafer 1-5 each PRN |mellitus |the exudate | | |antibiotic for infection |

|Hydrocortisone |Glucocorticoid and |Suppress fibroblast formation, |Steroid |HA, increased ICP, embolism, |Give oral drug with food, often |

| |Mineralocorticoid, |reduces capillary permeability and | |tachycardia, hyperglycemia, |alternate day regimen, stop |

| |anti-inflammatory |dilation, increases sensitivity to | |menstrual problems, , blurred |gradually, increase dose with |

| |Use: replacement therapy for |catecholamines, promotes Na+ | |vision, electrolyte imbalance, HT, |stress of illness or surgery, |

| |adrenal insufficiency, suppress |retension and K+ excretion, | |CHF, thrombocytopenia, acne, thin |monitor wt, CBC, BP, BS, albumin, |

| |immune and inflammatory responses |increases glomerular filtration, | |skin, weakness, delayed wound |electrolytes |

| | |promotes protein and fat metabolism| |healing, masked infection, muscle | |

| | |of liver | |wasting, cataracts, osteoporosis, | |

| | | | |hyperglycemia | |

|Hydrocortisone 50 mg IV q12h, |Glucocorticoid |Decrease inflammation |Steroid |Sweating, embolism, tach, edema, |K+, glucose, I&O, edema, weight, |

| | | | |fungal infections, diarrhea, N&V, |infection, WBC, mental status, |

| | | | |Thrombocytopenia, secondary |inflammation |

| | | | |infection | |

|Hydrolazin (alpresoline) |Vasodilator long action |Direct peripheral arteriolar |Cardiac Medication |Hypotension, tachycardia |Take with food, monitor wt, edema, |

| |Use: treat HTN by decreasing BP and|vasodilator | |Angina, dysrhythmias, edema, |may b e toxic with vit B, sexual |

| |decreasing afterload | | |peripheral neuritis, fever, |dysfunction, caution OTC cold meds |

| | | | |tingling.GI | |

| | | | |upset | |

|Hydromorphone HCl (Dilaudid) |Opioid, semi-synthetic |Bind to opioid receptors in CNS and| | Side effects less than morphine: |IV dilute in at least 5 ml .9ns, 2 |

| |Use: analgesic for moderate to |CSF to inhibit nociceptive pain, | |Constipation, N&V, drowsy, resp |mg over 3-5 min, assess baseline |

| |severe pain and anxiety inhibit | | |depressn, |resp rate and rhythm and pupil |

| |cough | | |Orthostatic hypotension, urinary |size, may produce reduced sigh |

| | | | |retension |leading to atelectasis, bowel |

| | | | | |protocol, avoid ETOH |

|Hydromorphone HCl (Dilaudid) |Opioid, semi-synthetic |Bind to opioid receptors in CNS and| |Side effects less than morphine: |IV dilute in at least 5 ml .9ns, 2 |

| |Use: analgesic for moderate to |CSF to inhibit nociceptive pain, | |Constipation, n&v, drowsy, resp |mg over 3-5 min, assess baseline |

| |severe pain and anxiety inhibit | | |depressn, |resp rate and rhythm and pupil |

| |cough | | |Orthostatic hypotension, urinary |size, may produce reduced sigh |

| | | | |retension |leading to atelectasis, bowel |

| | | | | |protocol, avoid ETOH |

|Hydromorphone hydrochloride |narcotic analgesic |7-10 times more analgesic than |analgesia for moderate to severe |respiratory depression, apnea, |document type, location, onset, and|

|(Dilaudid) | |morphine with a shorter duration of|pain, can be used in concentration |layngospasm, flushing, insomnia, |characteristics of symptoms, use a |

| | |action; manifests less sedation, |for those tolerant to narcotics |constipation, sedation |rating scale to rate pain; assess |

| | |less vomiting, and less nausea than| | |for respiratory depression, do not |

| | |morphine, although it produces | | |stop suddenly with long term use, |

| | |pronounced resp depression | | |increase intake of fluids and fiber|

| | | | | |to offset constipating effects |

|Hydromorphone hydrochloride |narcotic analgesic |7-10 times more analgesic than |analgesia for moderate to severe |respiratory depression, apnea, |document type, location, onset, and|

|(Dilaudid) | |morphine with a shorter duration of|pain, can be used in concentration |laryngospasm, flushing, insomnia, |characteristics of symptoms, use a |

| | |action; manifests less sedation, |for those tolerant to narcotics |constipation, sedation |rating scale to rate pain; assess |

| | |less vomiting, and less nausea than| | |for respiratory depression, do not |

| | |morphine, although it produces | | |stop suddenly with long term use, |

| | |pronounced resp depression | | |increase intake of fluids and fiber|

| | | | | |to offset constipating effects |

|Hydroxide (Milk of Magnesia ) 30 ml |Laxative saline; antacid |Increases osmotic pressure, draws, |Laxative |Muscle weakness, sweating, |I&O, constipation, cramping, MG |

| | |fluid into colon, neutralizes HCL | |confusion, flaccidity, hypothermia,|toxicity, thirst, confusion, |

| | | | |heart block, N&V, Electrolyte, |blurred vision, edema in feet, |

| | | | |fluid imbalance | |

|Hydroxyurea, Ddroxia, Hydrea |antimetabolities |unknown thought to inhibit DNA |resistant chronic myelocytic |GI effects, leukopenia, |monitor BUN, uric acid, creatinine |

| | |synthesis |leukemia, and other cancers |thrombocytopenia, bone marrow |levels, blood test every 2 wks, I &|

| | | | |suppression hyperuricemia, sz, |O and keep pt well hydrated, |

| | | | |hallucinations, HA, dizziness, |allopurinol is given for prevention|

| | | | |disorientaion, malaise |of tumor lysis syndrome, WBC count,|

| | | | | |labs are expected to be abnormal |

| | | | | |however toxic when neutrophil |

| | | | | | ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download